Screener
Amylyx Pharmaceuticals, Inc. AMLX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $49.33M-15.1% | $229.14M+283% | $226.65M+193% | $225.18M+213% | $58.09M-22.6% | ||
| $201.43M+64.1% | $50.63M-64.9% | $90.33M-8.9% | $118.81M-26.9% | $122.74M-47.7% | ||
| $256.34M+37.2% | $285.02M+31.9% | $323.67M+70.9% | $353.38M+44.1% | $186.89M-42.8% | ||
| $199K-55.3% | $212K-74.0% | $310K-67.7% | $399K-68.1% | $445K-69.8% | ||
| $264.56M+36.0% | $293.6M+33.7% | $332.65M+71.8% | $362.74M+44.7% | $194.6M-41.4% | ||
| $5.53M+68.0% | $3.53M-26.6% | $3.52M+19.7% | $5.34M+259% | $3.29M-33.5% | ||
| $21.15M-1.3% | $15.97M-11.0% | $22.69M-20.1% | $25.79M-52.2% | $21.42M-69.4% | ||
| $25.4M-5.0% | $20.44M+12.0% | $27.39M-5.1% | $30.75M-43.6% | $26.72M-62.3% | ||
| $11K+22.2% | $11K+22.2% | $11K+57.1% | $11K+57.1% | $9K+28.6% | ||
| -$836.13M-22.2% | -$792.71M-23.4% | -$751.43M-23.9% | -$718.43M-26.2% | -$684.04M-37.8% | ||
| $239.17M+42.5% | $273.16M+35.6% | $305.26M+85.3% | $332M+69.2% | $167.88M-35.8% | ||
| $264.56M+36.0% | $293.6M+33.7% | $332.65M+71.8% | $362.74M+44.7% | $194.6M-41.4% |
FAQ
- What are Amylyx Pharmaceuticals, Inc.'s total assets?
- Amylyx Pharmaceuticals, Inc. (AMLX) holds $264.6M in total assets, up 35.9% year over year.
- How much debt does Amylyx Pharmaceuticals, Inc. have?
- Amylyx Pharmaceuticals, Inc. carries $5.3M in total debt against $239.2M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Amylyx Pharmaceuticals, Inc. have?
- Amylyx Pharmaceuticals, Inc. holds $49.3M in cash and equivalents.
- Can Amylyx Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 12.12 — current assets exceed current liabilities.
- Where does Amylyx Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.